Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC

Cetuximab is a widely used drug for treating head and neck squamous cell carcinomas(HNSCCs);however,it provides restricted clinical benefits,and its response duration is limited by drug resistance.Here,we conducted randomized“Phase II-like clinical trials”of 49 HNSCC PDX models and reveal multiple informative biomarkers for intrinsic resistance to cetuximab(e.g.,amplification of ANKH,up-regulation of PARP3).After validating these intrinsic resistance biomarkers in another HNSCC PDX cohort(61 PDX models),we generated acquired cetuximab resistance PDX models and analyzed them to uncover resistance mechanisms.Whole exome sequencing and transcriptome sequencing revealed diverse patterns of clonal selection in acquired resistant PDXs,including the emergence of subclones with strongly activated RAS/MAPK.Extending these insights,we show that a combination of a RAC1/RAC3 dual-target inhibitor and cetuximab could overcome acquired cetuximab resistance in vitro and in vivo.Beyond revealing intrinsic resistance biomarkers,our PDX-based study shows how clonal architecture changes underlying acquired resistance can be targeted to expand the therapeutic utility of this important drug to more HNSCC patients.